Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent article by Hermann Einsele et al. published in The Lancet Oncology:
“CARTITUDE-4 update: deeper and more durable benefit with cilta-cel
Updated results from the phase 3 CARTITUDE-4 trial show that a single infusion of ciltacabtagene autoleucel (cilta-cel) continues to deliver substantial long-term benefit in lenalidomide-refractory multiple myeloma.
Efficacy highlights (median follow-up ~34 months):
- PFS: Not reached with cilta-cel vs 11.8 months with standard of care (HR 0.29)
- OS: Not reached with cilta-cel vs standard of care (HR 0.55; p=0.0009)
- Benefit observed after 1–3 prior lines of therapy
Trial context:
- Global, randomized phase 3 study across 81 sites
- Compared cilta-cel vs pomalidomide-based standard regimens
- Included earlier-line, lenalidomide-refractory patients
Safety:
- Higher rates of cytopenias with cilta-cel, consistent with CAR T therapy
- Serious adverse events occurred at similar rates across arms
- Fewer deaths overall in the cilta-cel group vs standard of care
Takeaway:
These longer-term data reinforce cilta-cel as a highly effective option early after first relapse, supporting a shift toward earlier CAR T-cell therapy in relapsed/refractory multiple myeloma.”
Title: Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Authors: Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen, Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh, Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schecter, Nikoletta Lendvai, Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh Popat
Read the Full Article on The Lancet Oncology
More posts featuring Yan Leyfman.